Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab in severe persistent asthma
NCT00207740Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2004
- Primary completion
- Jul 2007
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of golimumab in asthma (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Change From Baseline in Prebronchodilator Clinic-Measured, Percent-Predicted Forced Expiratory Volume in 1 Second at 24 weeks and Number of Severe Asthma Exacerbations Per Patient From Baseline Through 6 Months. Started Aug 2004; status: completed.
02
Drugs
golimumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00207740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00207740.